BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...
BOSTON, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
A study investigating the functional connectivity of the praxis network in patients in the early stages of Parkinson’s disease (PD) found that dopaminergic therapy may normalize praxis abilities and ...
I maintain a Hold rating on Praxis Precision Medicines, Inc., driven by positive open-label Radiant data for vormatrigine in epilepsy but tempered by clinical risks. Vormatrigine achieved a 56.3% ...
On Tuesday, Truist Securities maintained a Buy rating and a $150.00 stock price target for Praxis Precision Medicines Inc. (NASDAQ: PRAX), following the announcement of positive results from their ...
Praxis Precision Medicines, Inc. ( (PRAX)) has released its Q2 earnings. Here is a breakdown of the information Praxis Precision Medicines, Inc. presented to its investors. Take advantage of TipRanks ...
Hosted on MSN
Praxis Precision Medicines’ PRAX-628 Study: A Potential Game-Changer for Focal Seizures
Praxis Precision Medicines, Inc. ((PRAX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Praxis Precision Medicines has reported a 56.3% median reduction in seizure frequency from baseline in a midphase trial, encouraging the biotech to push ahead with phase 2/3 plans despite almost a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback